- ProductsInvestment SuiteExclusiveFeatures
- PlatformTrading PlatformsFeatures and ToolsCalculatorsPricing
- ResearchResearch CallsResearch Reports
- MarketStocksIndicesMutual FundsIPO
- LearnStockshaalaResourceInvesting GuideEvents
- Partner
- Support
Products
Platform
Research
Market
Learn
Compare UTI Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.25 | 1.94 |
NAV | ₹269.10 | ₹37.11 |
Fund Started | 01 Aug 2005 | 25 Jun 2018 |
Fund Size | ₹1042.04 Cr | ₹4914.64 Cr |
Exit Load | Exit load of 1% if redeemed within 30 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹500
₹100
Expense Ratio
2.25
1.94
NAV
₹269.10
₹37.11
Fund Started
01 Aug 2005
25 Jun 2018
Fund Size
₹1042.04 Cr
₹4914.64 Cr
Exit Load
Exit load of 1% if redeemed within 30 days.
Exit load of 1% if redeemed within 15 days.
Returns
1 Year | 19.86% | 20.60% |
3 Year | 20.12% | 24.15% |
5 Year | 21.87% | 25.12% |
1 Year
19.86%
20.60%
3 Year
20.12%
24.15%
5 Year
21.87%
25.12%
Holding Analysis
Equity | 99.21% | 98.28% |
Cash | 0.78% | 1.72% |
Equity
99.21%
98.28%
Cash
0.78%
1.72%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.65% |
Cipla Ltd. | 5.81% |
Ajanta Pharma Ltd. | 4.40% |
Dr. Reddy's Laboratories Ltd. | 4.35% |
Glenmark Pharmaceuticals Ltd. | 4.07% |
Procter & Gamble Health Ltd. | 3.65% |
Apollo Hospitals Enterprise Ltd. | 3.57% |
Fortis Healthcare Ltd. | 3.12% |
Divi's Laboratories Ltd. | 3.10% |
Alkem Laboratories Ltd. | 2.99% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 13.50% |
Dr. Reddy's Laboratories Ltd. | 8.95% |
Cipla Ltd. | 8.85% |
Divi's Laboratories Ltd. | 6.71% |
Aurobindo Pharma Ltd. | 5.30% |
Lupin Ltd. | 4.73% |
Alkem Laboratories Ltd. | 4.42% |
Mankind Pharma Ltd. | 3.50% |
Gland Pharma Ltd. | 3.39% |
Zydus Lifesciences Ltd. | 3.10% |
Fund Manager
Name | Kamal Gada | Dharmesh Kakkad |
Start Date | 02 May 2022 | 23 Feb 2021 |
Name
Kamal Gada
Dharmesh Kakkad
Start Date
02 May 2022
23 Feb 2021
About Fund
Description | The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 01 Aug 2005 | 25 Jun 2018 |
Description
The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
01 Aug 2005
25 Jun 2018